Intellia Therapeutics, Inc. ( NTLA) - Stock Earnings
NTLA Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Aug. 6, 2026, midnight | — / — | — | — / — | — |
NTLA Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | -101.3 million USD | 13.8 million USD |
| 2025Q4 | -95.8 million USD | 23.0 million USD |
| 2026Q1 | -96.2 million USD | 15.0 million USD |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
NTLA Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -481.2 million USD | 36.3 million USD |
| 2024 | -519.0 million USD | 57.9 million USD |
| 2025 | -412.7 million USD | 67.7 million USD |
| 2026 Est. | — | — |
NTLA
Price: $10.73
52 week price:
Earnings Per Share: -3.52 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.1 million
Ebitda: -15.1 millionMarket Capitalization: 2.0 billion